The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 2, 2012, Pages 164-171

  Jeong, Soung Won ^a   Jang, Jae Young ^a   Lee, Ji Eun ^a   Lee, Sae Hwan ^a   Kim, Sang Gyune ^a   Cha, Sang Woo ^a   Kim, Young Seok ^a   Cho, Young Deok ^a   Kim, Hong Soo ^a   Kim, Boo Sung ^a   Kim, Kyoung Ha ^a   Kim, Yong Jae ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Alternative treatment; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; High cost; Sorafenib

Indexed keywords

CISPLATIN; FLUOROURACIL; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOUDENUM ULCER; DRUG DOSE REDUCTION; DRUG INFUSION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SKIN REACTION; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HUMAN; LIVER CELL CARCINOMA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84860251803     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01543.x     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
4. Llovet JM, Di Bisceglie AM, Bruix J etal. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
5. Okuda K, Ohtsuki T, Obata H etal. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-28.
6. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 1995-2004.
7. Wilhelm SM, Carter C, Tang L etal. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
8. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76.
9. Chang YS, Adnane J, Trail PA etal. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-74.
10. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
11. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
12. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-47.
13. Atiq OT, Kemeny N, Niedzwiecki D, Botet J. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. Cancer 1992; 69: 920-4.
14. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-6.
15. Seno H, Ito K, Kojima K, Nakajima N, Chiba T. Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. J Gastroenterol Hepatol 1999; 14: 811-16.
16. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-95.
17. Itamoto T, Nakahara H, Tashiro H etal. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002; 80: 143-8.
18. Tanioka H, Tsuji A, Morita S etal. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23: 1891-7.
19. Murata K, Shiraki K, Kawakita T etal. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 2003; 23: 1719-22.
20. Ahn SH, Han KH, Park JY etal. Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM stage IVa). Yonsei Med J 2004; 45: 847-58.
21. Miura T. Intra-arterial infusion chemotherapy for advanced cancer - 40years of experience. Gan to Kagaku Ryoho 2005; 32: 1618-22.
22. Park JY, Ahn SH, Yoon YJ etal. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-37.
23. Woo HY, Bae SH, Park JY etal. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010; 65: 373-82.
24. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
25. Lacouture ME, Wu S, Robert C etal. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001-11.
26. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
27. Mondazzi L, Bottelli R, Brambilla G etal. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 1994; 19: 1115-23.
28. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14: 717-25.
29. Lee S, Yoon SH, Park JY etal. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Invest New Drugs 2011; [Epub ahead of print].
30. Kim HY, Park JW, Nam BH etal. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol 2011; doi: 10.1111/ [Epub ahead of print].
31. Yang MY, Jeong SW, Kim DK etal. Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy. Gut Liver 2010; 4: 423-7.